Kaylee A. Clark, PharmD describes the basic principles of maintenance therapies after allogeneic HSCT, discusses evidence and guideline recommendations for maintenance therapies after allogeneic HSCT for acute lymphoblastic leukemia and reviews evidence and guideline recommendations for maintenance therapies after allogeneic HSCT for acute myeloid leukemia.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.